Janux Therapeutics (NASDAQ:JANX) Insider Sells $56,947.77 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the sale, the insider owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. This trade represents a 5.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock traded up $0.17 during trading on Thursday, hitting $13.76. The stock had a trading volume of 621,032 shares, compared to its average volume of 914,938. The firm has a market cap of $839.08 million, a P/E ratio of -7.48 and a beta of 2.53. The business has a fifty day moving average of $14.51 and a two-hundred day moving average of $15.58. Janux Therapeutics, Inc. has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. As a group, research analysts forecast that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on JANX. Weiss Ratings upgraded Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Cantor Fitzgerald reduced their target price on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating for the company in a report on Friday, February 27th. JonesTrading reduced their target price on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, April 28th. UBS Group downgraded Janux Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $57.00 to $15.00 in a report on Wednesday, April 15th. Finally, Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.85.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Janux Therapeutics by 8.6% during the first quarter. Bank of America Corp DE now owns 801,646 shares of the company’s stock valued at $11,143,000 after purchasing an additional 63,316 shares during the last quarter. Irenic Capital Management LP acquired a new position in Janux Therapeutics during the first quarter valued at $10,645,000. ADAR1 Capital Management LLC raised its position in Janux Therapeutics by 21.6% during the first quarter. ADAR1 Capital Management LLC now owns 298,546 shares of the company’s stock valued at $4,150,000 after buying an additional 53,094 shares during the period. Rock Springs Capital Management LP raised its position in Janux Therapeutics by 2.3% during the first quarter. Rock Springs Capital Management LP now owns 367,009 shares of the company’s stock valued at $5,101,000 after buying an additional 8,211 shares during the period. Finally, Quantinno Capital Management LP raised its position in Janux Therapeutics by 7.6% during the first quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock valued at $362,000 after buying an additional 1,846 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.